CD7CAR
Showing 76 - 100 of >10,000
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)
Completed
- Acute Lymphoblastic Leukemia
- CAR-NK-CD19 Cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Nov 24, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 3, 2022
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma Trial in Stanford (Fludarabine, Cyclophosphamide, Autologous
Suspended
- B Cell Lymphoma
- +2 more
- Fludarabine
- +2 more
-
Stanford, CaliforniaStanford Medical Center
Sep 8, 2022
Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)
Recruiting
- Acute Lymphocytic Leukemia
- CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023
B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,
Active, not recruiting
- B-Cell Acute Lymphoblastic Leukemia, Adult
- +2 more
- Fludarabine
- +2 more
-
Maywood, IllinoisLoyola University
Aug 11, 2022
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
RRMM Trial in Lishui, Wenzhou (CAR-T therapy in Relapsed/Refractory multiple myeloma)
Unknown status
- RRMM
- CAR-T therapy in Relapsed/Refractory multiple myeloma
-
Lishui, Zhejiang, China
- +2 more
Nov 16, 2020
SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)
Recruiting
- SLE (Systemic Lupus)
- +4 more
- CD19 targeted CAR-T cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Sep 25, 2023
Langerhans Cell Histiocytosis Trial in Beijing (CD207 CAR-T cells)
Not yet recruiting
- Langerhans Cell Histiocytosis
- CD207 CAR-T cells
-
Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Jul 25, 2022
Acute Myeloid Leukemia Trial in Fuzhou (CLL1/+CD33 CAR-T)
Not yet recruiting
- Acute Myeloid Leukemia
- CLL1/+CD33 CAR-T
-
Fuzhou, Fujian, ChinaFujian Provincial Children's Hospital
Jul 10, 2023
Myasthenia Gravis Trial in Hangzhou (CD19 CAR-T cells injection)
Recruiting
- Myasthenia Gravis
- CD19 CAR-T cells injection
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023
Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023
B-cell Non-Hodgkin's Lymphoma Trial in Shanghai (Human CD19Targeted T Cells Injection)
Recruiting
- B-cell Non-Hodgkin's Lymphoma
- Human CD19Targeted T Cells Injection
-
Shanghai, Shanghai, ChinaZhongshan Hospital, Fudan University
Jun 29, 2022
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Neuromyelitis Optica Trial in Hangzhou (CD19 CAR-T cells injection)
Recruiting
- Neuromyelitis Optica
- CD19 CAR-T cells injection
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Apr 12, 2023
Acute Myeloid Leukemia Trial in Beijing, Shenzhen, Haikou (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)
Recruiting
- Acute Myeloid Leukemia
- CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)
Not yet recruiting
- Hematological Malignancy
- Fludarabine Phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
CAR-T Trial in Hangzhou (GC012F injection)
Recruiting
- CAR-T
- GC012F injection
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
May 10, 2023
Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)
Not yet recruiting
- Glioblastoma Multiforme of Brain
- CHM-1101 CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 19, 2022
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Anti-CD33 CAR T-cells
- Lymphodepletion Therapy
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023